# OnCo record paper-ascend-4-lancet-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ascend-4-lancet-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ascend-4-lancet-2017" ;
  schema:name "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study"@en ;
  schema:description "The primary report of ASCEND-4: untreated ALK-positive lung cancer stayed under control for a median of 16.6 months on ceritinib against 8.1 months on platinum chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-ascend-4-lancet-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(17)30123-X>, <https://pubmed.ncbi.nlm.nih.gov/28126333/>, <https://clinicaltrials.gov/study/NCT01828099> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(17)30123-X> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Soria JC, Tan DSW, Chiari R, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/ceritinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct01828099/> ;
  onco:people <https://onco.cc/people/jean-charles-soria/>, <https://onco.cc/people/luis-paz-ares/>, <https://onco.cc/people/juergen-wolf/>, <https://onco.cc/people/chong-jen-yu/> ;
  onco:journals <https://onco.cc/journals/lancet/> .